UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/18.09.24

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/18.09.24 Share Price

DE000HC9M0W6

Real-time BOERSE MUENCHEN 07:11:46 27/06/2024 pm IST
3.84 ^EUR	+2.13%

Current month	+21.68%
1 month	+20.13%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/18.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	02:58pm	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	25/06	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	24/06	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	22/06	MT

More news

Quotes 5-day view

Date	Price	Change
27/24/27	3.84	+2.13%
26/24/26	3.76	+1.08%
25/24/25	3.72	-5.34%
24/24/24	3.93	+9.78%
21/24/21	3.58	-4.02%

Real-time BOERSE MUENCHEN

Last update June 27, 2024 at 07:11 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HC9M0W
ISIN	DE000HC9M0W6
Date issued	02/10/2023
Strike	450 $
Maturity	18/09/2024 (83 Days)
Parity	10 : 1
Emission price	1.69 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.98 €
Lowest since issue	1.04 €
Delta	0.73x
Omega	8.399
Premium	3.27x
Gearing	11.48x
Moneyness	1.058
Difference Strike	-25.28 $
Difference Strike %	-5.62%
Spread	0.04 €
Spread %	1.03%
Theoretical value	3.780
Implied Volatility	25.73 %
Total Loss Probability	31.99 %
Intrinsic value	2.281
Present value	1.499
Break even	490.46 €
Theta	-0.11x
Vega	0.07x
Rho	0.06x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

474 USD

Average target price

468.3 USD

Spread / Average Target

-1.21%

Consensus